
|Articles|June 1, 2014
EU Steps Up Manufacturing Inspection Efforts
Author(s)Guest Blogger
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.
Advertisement
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”. The European Directorate for the Quality of Medicines & Healthcare, which is responsible for the European Pharmacopoeia but also runs its own inspection operations, has been tightening and updating guidelines on the testing of products.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Why Integrated GMP Operating Models Are Reshaping Outsourced Manufacturing
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
5




